Literature DB >> 33613024

Neurologic manifestations of COVID-19 infection in Asia: a systematic review.

I Putu Eka Widyadharma1, Alvin Hendellyn1, A A A Putri Laksmi Dewi1, I Made Oka Adnyana1, D P G Purwa Samatra1, Desak Ketut Indrasari Utami1.   

Abstract

BACKGROUND: COVID-19 infection can show various manifestation, including neurologic manifestations, such as anosmia, ageusia, or dysgeusia, and causes the neurologic disorder such as stroke, Guillain-Barre syndrome, encephalopathy, and many more. AIM: To briefly review neurologic manifestation in COVID-19 infection in the Asia region (South East Asia and the Western Pacific Region).
MATERIAL AND METHODS: This review uses the PRISMA statement and checklist. The source for reviewed article was performed in PubMed that were published between December 2019 to September 2020 with the latest 1 year of publication. Study titles were first screened, then reviewed by title and abstract and then the last review, we tested full text and applied eligibility criteria.
RESULTS: We found a total of 9 retrieved articles from the electronic database. Among these 9 articles, 5 of them are case report, 1 case series, 1 prospective multi-center cohort study, 1 retrospective multi-center study, and 1 retrospective observational study. All articles reported confirmed COVID-19, confirmation by positive swab test using the real-time RT-PCR method, with neurologic manifestations, disorder, or syndrome on presentation or found during hospital stay. In case of neurologic disorder or syndrome, the studies reported encephalitis and ADEM, acute cerebrovascular disease, acute symptomatic seizure, and Guillain-Barré syndrome with acute cerebrovascular disease as the most common neurologic disorder associated with COVID-19 infection, followed by encephalitis.
CONCLUSION: COVID-19 also affects the brain, which may result in a global or focal neurologic manifestation. Healthcare provider treating patient with COVID-19 infection should also be aware of neurologic manifestation associated with COVID-19 infection to improve patient's outcome.Guillain-Barre syndrome, encephalopathy, and many more. This review will briefly review neurologic manifestation in COVID-19 infection in the Asian region (South East Asia and the Western Pacific Region. A total of 9 retrieved articles from the electronic database reported confirmed COVID-19, confirmation by RT-PCR method, with neurologic manifestation, disorder, or syndrome on presentation or found during hospital stay. Healthcare provider treating patient with COVID-19 infection should also be aware of neurologic manifestation associated with COVID-19 infection to improve patient's outcome.
© The Author(s) 2021.

Entities:  

Keywords:  Neurologic manifestation, COVID-19, Systematic review

Year:  2021        PMID: 33613024      PMCID: PMC7887564          DOI: 10.1186/s41983-021-00279-3

Source DB:  PubMed          Journal:  Egypt J Neurol Psychiatr Neurosurg        ISSN: 1110-1083


  14 in total

Review 1.  Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

Authors:  James J Sejvar; Andrew L Baughman; Matthew Wise; Oliver W Morgan
Journal:  Neuroepidemiology       Date:  2011-03-21       Impact factor: 3.282

2.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 3.  Cytokines and acute neurodegeneration.

Authors:  S M Allan; N J Rothwell
Journal:  Nat Rev Neurosci       Date:  2001-10       Impact factor: 34.870

4.  An interferon-gamma-related cytokine storm in SARS patients.

Authors:  Kao-Jean Huang; Ih-Jen Su; Michel Theron; Yi-Chun Wu; Shu-Kuan Lai; Ching-Chuan Liu; Huan-Yao Lei
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

5.  Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection.

Authors:  Shinichi Wada; Yoji Nagasaki; Yoko Arimizu; Masatoshi Shimo; Yuta Matsukuma; Masaki Okamoto; Shinichiro Yoshida; Ikkei Ohashi; Go Hashimoto; Takahiro Kuwashiro; Masahiro Yasaka; Yasushi Okada
Journal:  Intern Med       Date:  2020-07-21       Impact factor: 1.271

6.  New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study.

Authors:  Lu Lu; Weixi Xiong; Dan Liu; Jing Liu; Dan Yang; Nian Li; Jie Mu; Jian Guo; Weimin Li; Gang Wang; Hui Gao; Yingying Zhang; Mintao Lin; Lei Chen; Sisi Shen; Hesheng Zhang; Josemir W Sander; Jianfei Luo; Shengli Chen; Dong Zhou
Journal:  Epilepsia       Date:  2020-05-02       Impact factor: 5.864

7.  Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report.

Authors:  Maomao Wang; Ting Li; Fan Qiao; Laixing Wang; Chunlin Li; Yanping Gong
Journal:  Medicine (Baltimore)       Date:  2020-09-04       Impact factor: 1.889

8.  Characteristics of Acute Stroke in Patients with Coronavirus Disease 2019 and Challenges in Stroke Management during an Epidemic.

Authors:  Doo Hyuk Kwon; Youngrok Do; Mi Yeon Eun; Jun Lee; Hyungjong Park; Sung Il Sohn; Jeong Ho Hong
Journal:  J Korean Med Sci       Date:  2020-09-07       Impact factor: 2.153

9.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

10.  Cerebrospinal fluid confirmed COVID-19-associated encephalitis treated successfully.

Authors:  Yasmine Mohamed Kamal; Yasmin Abdelmajid; Abubaker Abdul Rahman Al Madani
Journal:  BMJ Case Rep       Date:  2020-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.